Tracers / [68Ga]177-AAZTA5-PSMA-617
[68Ga]177-AAZTA5-PSMA-617
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- AAZTA5-PSMA-617 (urea-based PSMA-targeting small molecule with AAZTA5 chelator)
- Target / mechanism
- PSMA (prostate-specific membrane antigen) binding PMID 33242189
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/lu177-aazta5psma617/">lu177-aazta5psma617</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | >99% | 99.9% | AAZTA5-PSMA-617 | 33242189 2020 EJNMMI Radiopharm Chem Labeling with 68Ga and 177Lu were performed in 1 ml of 0.2 M ammonium acetate buffer pH 4.5 at room temperature (25 °C). — radiolabeled in quantitative radiochemical yields (> 99%, as determined both by radio-HPLC and radio-TLC) |
Need this precursor?We can point you to suppliers for [68Ga]177-AAZTA5-PSMA-617, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 33242189. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 33242189: 'AAZTA5-PSMA-617 (AAZTA5-Chx-2-NaI-Lys-Urea-Glu) was successfully radiolabeled'.